- Conditions
- H. Pylori Infection, Gastric Cancer, Gastritis H Pylori
- Interventions
- PYTEST® 14C-Urea Capsule Breath Test (at Home), PYTEST® 14C-Urea Capsule Breath Test (Standard Retesting In-Person)
- Drug
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 721–744
of 1,091
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Stomach Cancer, Gastric Cancer
- Interventions
- 5-Fluorouracil, Folinic Acid, Oxaliplatin, Radiotherapy, Surgery
- Drug · Radiation · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Small Bowel Cancer, Pancreatic Cancer
- Interventions
- Not listed
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Metastatic Cancer, Solid Tumor
- Interventions
- Sym021, Sym024
- Drug
- Lead sponsor
- Symphogen A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 3
- States / cities
- Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Adaptive short course radiation therapy, Standard of care chemotherapy regimen
- Radiation · Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Gastrointestinal Cancer
- Interventions
- Surgeon-palliative care team co management, Surgeon team alone management
- Other
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 379 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 5
- States / cities
- Stanford, California • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
- Interventions
- SEA-TGT, sasanlimab, brentuximab vedotin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Duarte, California + 22 more
- Conditions
- Breast Cancer, Small Cell Lung Cancer, Ovarian Cancer, Gastric Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced Solid Tumor, Endometrial Cancer, Prostate Cancer, TNBC - Triple-Negative Breast Cancer, GastroEsophageal Cancer, Bladder Cancer
- Interventions
- BG-68501, Fulvestrant, BGB-43395
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Lake Mary, Florida • St Louis, Missouri + 3 more
- Conditions
- Healthy, Barrett's Esophagus, Gastric Acid Reflux
- Interventions
- MGH SECM Imaging Capsule
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm, Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum, Metastatic Malignant Solid Neoplasm, Metastatic Ovarian Carcinoma, Pathologic Stage IV Gastric Cancer AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8, Stage IV Appendix Carcinoma AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Uterine Corpus Cancer AJCC v8, Stage IVA Appendix Carcinoma AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Uterine Corpus Cancer AJCC v8, Stage IVB Appendix Carcinoma AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8, Stage IVC Appendix Carcinoma AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Biopsy, Cisplatin, Doxorubicin, Fluorouracil, Intraperitoneal Chemotherapy, Irinotecan, Leucovorin, Mitomycin, Oxaliplatin, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Device + 1 more
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 3
- States / cities
- Duarte, California • Jacksonville, Florida • Greenlawn, New York
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- capecitabine, docetaxel
- Drug
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 28
- States / cities
- Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 20 more
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma Cancer, Metastatic Gastric Adenocarcinoma Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- zolbetuximab
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Morristown, New Jersey
- Conditions
- Cancers With HER2 Expression
- Interventions
- BAY2701439
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
- Conditions
- Gastro Esophageal Reflux, Barrett Esophagus, Erosive Esophagitis
- Interventions
- Confocal endomicroscopy, Endoscopic biopsies, Mucosal impedance (MI)
- Procedure · Diagnostic Test
- Lead sponsor
- McGuire Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Gastric Cancer
- Interventions
- Observational study (no intervention)
- Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Healthy
- Interventions
- Clopidogrel, Clopidogrel and Lansoprazole, Clopidogrel and Dexlansoprazole, Clopidogrel and Omeprazole, Clopidogrel and Esomeprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Gastric Cancer
- Interventions
- Ramucirumab (IMC-1211B) DP, Placebo, Paclitaxel
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 665 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 13
- States / cities
- Burbank, California • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Questionnaire Administration, Ramucirumab
- Procedure · Biological · Drug + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 224 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 378
- States / cities
- Little Rock, Arkansas • Anaheim, California • Baldwin Park, California + 287 more
- Conditions
- Solid Tumor
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- ONC-392, Pembrolizumab, Docetaxel
- Drug
- Lead sponsor
- OncoC4, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 733 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 33
- States / cities
- Springdale, Arkansas • Davis, California • Downey, California + 27 more
- Conditions
- Solid Tumor, Adult
- Interventions
- FT538, Cyclophosphamide, Fludarabine, Monoclonal antibody - Dose Escalation, Monoclonal antibody - Dose Expansion
- Drug · Combination Product
- Lead sponsor
- Fate Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Hackensack, New Jersey • Nashville, Tennessee • Houston, Texas + 1 more
- Conditions
- Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma
- Interventions
- Rucaparib, Ramucirumab, Nivolumab
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 8
- States / cities
- Chicago, Illinois • Fairway, Kansas • Kansas City, Kansas + 3 more
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Pancreatic Cancer, Quality of Life, Small Intestine Cancer
- Interventions
- bowel obstruction management, quality-of-life assessment
- Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2003
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
- Interventions
- Q702, Pembrolizumab
- Drug · Biological
- Lead sponsor
- Qurient Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Louisville, Kentucky